The flagship offering, the Clinical Trial Forecasting Lab, currently tracks over 600 active trials. The system generates probability estimates for meeting primary endpoints, with each forecast locked before results are public to ensure verifiable accuracy. Beyond forecasting, the platform supports complex tasks including drug repurposing, safety assessments, and interaction analysis.
Dr. Heng Ji, who leads the Drug Research Computing Center, explained that the platform functions as a comprehensive research environment rather than a standard language model. It utilizes agentic workflows and multi-hop mechanistic searches to build traceable evidence chains. According to CEO Tianqiao Chen, the initiative intends to ensure that the benefits of AI-driven drug discovery extend to human health outcomes rather than remaining restricted to firms with massive computing budgets. Interested researchers can access these tools through the Apodex portal, subject to agreed-upon terms.
Comments (0)
No comments yet. Be the first!